Jeitner Thomas M, Muma Nancy A, Battaile Kevin P, Cooper Arthur Jl
Applied Bench Core, Winthrop University Hospital, 222 Station Plaza North, Suite 502, Mineola, NY 11501, USA Tel.: +1 516 663 3455
Future Neurol. 2009 Jul 1;4(4):449-467. doi: 10.2217/fnl.09.17.
The following review examines the role of calcium in promoting the in vitro and in vivo activation of transglutaminases in neurodegenerative disorders. Diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease exhibit increased transglutaminase activity and rises in intracellular calcium concentrations, which may be related. The aberrant activation of transglutaminase by calcium is thought to give rise to a variety of pathological moieties in these diseases, and the inhibition has been shown to have therapeutic benefit in animal and cellular models of neurodegeneration. Given the potential clinical relevance of transglutaminase inhibitors, we have also reviewed the recent development of such compounds.
以下综述探讨了钙在促进神经退行性疾病中谷氨酰胺转移酶的体外和体内激活方面的作用。诸如阿尔茨海默病、帕金森病和亨廷顿病等疾病表现出谷氨酰胺转移酶活性增加以及细胞内钙浓度升高，这两者可能存在关联。钙对谷氨酰胺转移酶的异常激活被认为会在这些疾病中产生多种病理成分，并且在神经退行性变的动物和细胞模型中，抑制作用已显示出具有治疗益处。鉴于谷氨酰胺转移酶抑制剂潜在的临床相关性，我们还综述了此类化合物的最新进展。
